Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: JAMA Intern Med. 2014 Nov 1;174(11):1736–1745. doi: 10.1001/jamainternmed.2014.4052

Table 2.

Primary Outcome Analyses

Days of use of the primary drug of abuse
in the past 30 days at 3 month visit (Normal Model)
Label Estimate (95% CI) Unadjusted P-
values		 Adjusted P-values
MSO – BI-B 0.7174 (−0.8044, 2.2391) 0.3552 0.5749
SAR – BI-B 0.7003 (−0.8254, 2.2261) 0.3680 0.5749
SAR – MSO −0.01701 (−1.5327, 1.4987) 0.9824 0.9824
Baseline Use Days 0.4287 (0.3740, 0.4834) <.0001 .
DAST-10 Score −0.5581 (−0.8525, −0.2637) 0.0002 .
AUDIT-C Score −0.1811 (−0.3520, −0.01019) 0.0378 .
Site (Variance) 3.99 0.0830 .
Error (Variance) 113.62 <.0001 .
Days of use of the primary drug of abuse
in the past 30 days at 3 month visit (Beta Binomial Model)
Label Odds Ratio Estimate (95% CI) Unadjusted P-
values		 Adjusted P-values
MSO vs. BI-B 1.0622(0.8771, 1.2866) 0.6259 0.6259
SAR vs. BI-B 1.1798(0.9746, 1.4281) 0.1373 0.3491
SAR vs. MSO 1.1106 (0.9188, 1.3423) 0.3635 0.3635
Baseline Use Days 1.0559 (1.0485, 1.0634) <.0001 .
DAST-10 Score 0.8955 (0.8644, 0.9278) <.0001 .
AUDIT-C Score 0.9702 (0.9501, 0.9907) 0.0167 .